LyGenesis

Executive Summary

LyGenesis is a clinical-stage biotechnology company pioneering a novel cell therapy that transforms a patient's lymph nodes into bioreactors to grow functional ectopic organs, addressing the critical shortage of donor organs. Its lead program targets end-stage liver disease (ESLD) using an outpatient endoscopic ultrasound procedure, which reduces the risks and costs compared to traditional transplantation. The company has advanced to Phase 3 clinical trials, positioning it for potential regulatory milestones. By enabling a single donated organ to treat dozens of patients, LyGenesis could significantly expand access to life-saving therapies. The platform's innovative approach has the potential to disrupt the organ transplant market and address a substantial unmet medical need.

Upcoming Catalysts (preview)

• Q4 2026Phase 3 interim data readout for ESLD program70% success
• Q2 2027FDA meeting to discuss accelerated approval pathway60% success
• Q3 2026Strategic partnership or licensing deal for platform expansion50% success